NCT01018641CompletedPhase 1
A Phase 1 Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of 3 Ascending Dose Levels Of A 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Pfizer
- Enrollment
- 449
- Locations
- 6
- Primary Endpoint
- The primary immunogenicity endpoint in stage 1 is antigen-specific antibody levels using an Ig binding assay (Ig titers) 28 days after vaccination at visit 1 in the 50- to 85-year age stratum at each vaccine group (3 SA3Ag dose levels and placebo).
Study Overview
Brief Summary
This study is a first-in-human (Phase 1) study using three dose levels of an investigational vaccine directed against Staphylococcus aureus (SA3Ag). This study is primarily designed to assess how safe and well tolerated SA3Ag is, but will also describe the immune response over 12 months elicited by SA3Ag. Additionally, this study will assess the effect of SA3Ag vaccine on the number of Staphylococcus aureus bacteria that naturally occur on the skin and within the nose and throat.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy adults aged 18 to 24 years or 50 to 85 years who are available for the entire duration of the study, able to be contacted by phone, and able to complete all study procedures, including completion of an electronic diary (e-diary).
- •Men and women who are able to have children, must use a reliable method of birth control for the duration of the study.
Exclusion Criteria
- •Any major illness that would substantially increase the risk associated with participation in the study, or interfere with the evaluation of the study objectives - this is determined by the local physician.
- •Donation of 250 mL or more of blood within the last 3 months.
- •Condition associated with prolonged bleeding time, including subjects taking anticoagulant medication or antiplatelet therapy.
- •Any contraindication to vaccination or vaccine components.
- •Immunocompromised persons and subjects who receive treatment with immunosuppressive therapy.
- •Previous administration of S. aureus vaccination.
- •Receipt of blood products or immunoglobulins within 12 months prior to study
- •Participation in another trial (not including observational trials) within the last 30 days.
- •Study site personnel or immediate family members (first-degree relatives).
- •Women who are pregnant (as determined by urine pregnancy test) or breast-feeding.
- •Residence in a nursing home or long-term care facility or requirement for semiskilled nursing care.
- •For subjects aged 65 years or older, a Mini-Mental State Examination (MMSE) score of <=21.
Outcomes
Primary Outcomes
The primary immunogenicity endpoint in stage 1 is antigen-specific antibody levels using an Ig binding assay (Ig titers) 28 days after vaccination at visit 1 in the 50- to 85-year age stratum at each vaccine group (3 SA3Ag dose levels and placebo).
Time Frame: 1 month
The primary comparison of interest is a 2-fold increase in Ig titers relative to baseline for each antigen.
Time Frame: 1 month
Secondary Outcomes
- The safety endpoints are solicited and unsolicited AEs, SAEs, and hematologic and urine parameters.(12 months)
- OPA titers for each antigen 28 days after vaccination in both age strata at selected dose level cohort(s).(1 month)
- The secondary immunogenicity endpoints are Ig titers for each antigen (CP5, CP8, and rClfAm) 28 days after vaccination in the 18- to 24-year age stratum at each dose level cohort.(1 month)
- Ig titers for each antigen 28 days after the booster dose.(7 months)
Investigators
Study Sites (6)
Loading locations...
Similar Trials
Completed
Phase 1
Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 YearsClostridium Difficile Associated DiseaseNCT01706367Pfizer192
Completed
Phase 1
Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic FeverCrimean Congo Hemorrhagic FeverNCT06684431Karolinska Institutet15
Completed
Phase 1
Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy AdultsMalariaNCT02013687Fraunhofer, Center for Molecular Biotechnology44
Completed
Phase 1
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT06422520BeOne Medicines63
Terminated
Phase 1
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UKPlasmodium FalciparumMalariaNCT05400746University of Oxford17